Premium
Molecular Tumor Boards: Realizing Precision Oncology Therapy
Author(s) -
Patel Maulik,
Kato Shumei M.,
Kurzrock Razelle
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.920
Subject(s) - precision oncology , precision medicine , targeted therapy , clinical oncology , medicine , dna sequencing , computational biology , oncology , personalized medicine , medical physics , bioinformatics , gene , cancer , biology , pathology , genetics
Technological advances in high‐throughput next‐generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene‐ and immune‐targeted therapies, both of which impact the mutanome. Clinical implementation of this technology, approval of novel targeted agents, and establishment of molecular tumor boards has enabled precision oncology to become a reality.